The Medical Advisor

Home › GLP-1 Hub By Dr. Frank Yap, MD | One Day Media Network | Published October 13, 2026 | Last updated: October 13, 2026 | Purpose: evidence and safety education, not individual medical advice Quick Answer As of October 2026, the FDA has approved two GLP-1 weight-loss pills, oral Wegovy (semaglutide 25 mg, December 2025) and Foundayo (orforglipron, April 1, 2026), alongside weekly injections such as Wegovy, Zepbound, Ozempic and Mounjaro. Retatrutide and CagriSema are not approved in the US. Compounded and gray-market GLP-1 products are not FDA-approved. Use a licensed prescriber and a regulated pharmacy. On this page Which GLP-1 medicines are approved in October 2026? Are GLP-1 pills as effective as injections? Retatrutide and CagriSema: what is known so far? Safety and side effects: what should patients know? Compounded, gray-market and research peptides: what are the risks? How strong is the evidence? (CEBM grades) Where to start: the complete GLP-1 evidence library Using...

OneDayMD • The Medical Advisor A single starting point for exploring OneDayMD's health, wellness, longevity, nutrition, cancer, metabolic medicine, emerging therapies and digital-health research. Quick Answer OneDayMD is an independent health-information and research-synthesis platform covering conventional medicine, integrative health, longevity, nutrition, supplements, metabolic medicine, cancer research, emerging therapies and digital health. This Master Guide is the site's central navigation page: use it to find the right topic hub, then move from a broad guide to the specific evidence, study, therapy, supplement, condition or research question you are investigating. On this page Start Here · Core Health Hubs · Cancer & Oncology · Nutrition & Supplements · Longevity · GLP-1 & Metabolic Health · DMSO ·...